Internal Medicine, Hematology & Oncology · Flemington, NJ
NPI
1437393352
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2100 Wescott Dr
Flemington, NJ, 08822
Phone (908) 788-6461
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.7M
250,386 services
Medicare patients, 2024
548
Average age 75
Drug cost, 2024
$4.9M
1,672 prescriptions
Company payments, 2025
$4,220
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Megha Shah was code J1439 (injection, ferric carboxymaltose, 1 mg), 59,250 times for 40 patients. In total Megha Shah billed 250,386 services in 173 codes, and Medicare paid $3.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 59,250 | 40 | $0.88 | $52K |
| J0185 Injection, aprepitant, 1 mg | Office | 21,336 | 49 | $1.34 | $29K |
| J9264 Injection, paclitaxel protein-bound particles, 1 mg | Office | 16,197 | 12 | $10.66 | $173K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,601 | 12 | $44.61 | $651K |
| J9299 Injection, nivolumab, 1 mg | Office | 12,700 | 12 | $24.62 | $313K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 12,603 | 13 | $0.06 | $721 |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 11,500 | 40 | $4.39 | $50K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 7,392 | 25 | $21.39 | $158K |
| J0897 Injection, denosumab, 1 mg | Office | 6,842 | 63 | $20.60 | $141K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,918 | 73 | $0.09 | $266 |
| 85025 Blood Count | Office | 1,089 | 311 | $7.61 | $8,287 |
| 99213 Office E&M - Established | Office | 1,006 | 370 | $73.58 | $74K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 932 | 16 | $3.62 | $3,377 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 888 | 22 | $6.02 | $5,342 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 716 | 31 | $0.07 | $52.78 |
By year: 2022 $1.8M for 157,138 services; 2023 $1.8M for 172,612 services; 2024 $3.7M for 250,386 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,089 | 311 | $7.61 | $8,287 |
| 80053 Clinical Chemistry | 620 | 191 | $10.35 | $6,417 |
| 83615 Clinical Chemistry | 567 | 180 | $5.92 | $3,357 |
| 83735 Clinical Chemistry | 533 | 164 | $6.57 | $3,502 |
| 84100 Clinical Chemistry | 527 | 160 | $4.65 | $2,451 |
| 36415 Venipuncture Blood Collection | 245 | 158 | $8.65 | $2,119 |
| 86300 Immunoassay | 87 | 41 | $20.39 | $1,774 |
| 82378 Clinical Chemistry | 76 | 28 | $18.58 | $1,412 |
| 84443 Clinical Chemistry | 54 | 32 | $16.46 | $889 |
| 84439 Clinical Chemistry | 54 | 32 | $8.84 | $477 |
Medicare prescription drug claims, 2024
In 2024, the drug Megha Shah prescribed most often to Medicare patients was Anastrozole, with 485 prescriptions and refills. In total Megha Shah wrote 1,672 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 485 | 1,216 | 141 | $11K |
| Raloxifene Hcl Generic | 76 | 212 | 25 | $3,512 |
| Letrozole Generic | 70 | 191 | 22 | $1,658 |
| Procrit Epoetin Alfa | 41 | 41 | 17 | $145K |
| Eliquis Apixaban | 40 | 44 | Under 11 | $26K |
| Cinvanti Aprepitant | 38 | 38 | Under 11 | $20K |
| Lupron Depot Leuprolide Acetate | 35 | 67 | Under 11 | $128K |
| Oxycodone Hcl Generic | 30 | 30 | 19 | $750 |
| Ondansetron Hcl Generic | 29 | 29 | 12 | $132 |
| Verzenio Abemaciclib | 28 | 28 | Under 11 | $308K |
| Hydroxyurea Generic | 28 | 75 | Under 11 | $540 |
| Venclexta Venetoclax | 27 | 27 | Under 11 | $199K |
| Acyclovir Generic | 26 | 58 | Under 11 | $594 |
| Imbruvica Ibrutinib | 25 | 25 | Under 11 | $418K |
| Neulasta Pegfilgrastim | 24 | 24 | Under 11 | $187K |
Brand drugs: 554 claims; generic drugs: 1,118 claims; opioid claims: 43.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Megha Shah $4,220 ($4,220 in general payments such as food, travel and fees) from 31 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $2,107.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 6 | $2,107 |
| Daiichi Sankyo Inc. 4568.T | 12 | $1,153 |
| Pfizer Inc. PFE | 4 | $106 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $84.83 |
| Gilead Sciences, Inc. GILD | 4 | $72.72 |
| Abbvie Inc. ABBV | 4 | $69.72 |
| GlaxoSmithKline, LLC. GSK | 3 | $56.23 |
| Sobi, Inc SOBI.ST | 3 | $52.78 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $48.93 |
| Genzyme Corporation SNY | 2 | $40.03 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.